ENLV
Enlivex Ltd. (NASDAQ)
Healthcare — Biotechnology
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Price History
Fundamentals
| Market Cap | $130.55M |
| P/E Ratio (TTM) | 0.02 |
| Forward P/E | -0.69 |
| EPS (TTM) | $25.48 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | 126.17% |
| Debt/Equity | 0.03 |
| Recommendation | None |
| Analyst Target | $20.00 |
| Analysts | 1 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 24.1 |
| Beta | 1.47 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $2.10 |
| 52-Week Low | $0.52 |
| 50-Day Avg | $0.74 |
| 200-Day Avg | $0.94 |
| Avg Volume | 435.1K |
| Volume | 684.9K |
Performance Analysis
BULLISHENLV shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:07 UTC
Back to Screener Export Report